These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34733290)

  • 1. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor.
    Wang C; Zainal NS; Chai SJ; Dickie J; Gan CP; Zulaziz N; Lye BKW; Sutavani RV; Ottensmeier CH; King EV; Abraham MT; Ismail SMB; Lau SH; Kallarakkal TG; Mun KS; Zain RB; Abdul Rahman ZA; Thomas GJ; Cheong SC; Savelyeva N; Lim KP
    Front Immunol; 2021; 12():763086. PubMed ID: 34733290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized cancer vaccination in head and neck cancer.
    Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
    Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients.
    Chai SJ; Fong SCY; Gan CP; Pua KC; Lim PVH; Lau SH; Zain RB; Abraham T; Ismail SM; Abdul Rahman ZA; Ponniah S; Patel V; Cheong SC; Lim KP
    Hum Vaccin Immunother; 2019; 15(1):167-178. PubMed ID: 30193086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
    Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer.
    Kono M; Wakisaka R; Komatsuda H; Hayashi R; Kumai T; Yamaki H; Sato R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Kobayashi H; Hayashi T; Takahara M
    Head Neck; 2024 Aug; 46(8):2056-2067. PubMed ID: 38390628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.
    Tan YS; Sansanaphongpricha K; Xie Y; Donnelly CR; Luo X; Heath BR; Zhao X; Bellile E; Hu H; Chen H; Polverini PJ; Chen Q; Young S; Carey TE; Nör JE; Ferris RL; Wolf GT; Sun D; Lei YL
    Clin Cancer Res; 2018 Sep; 24(17):4242-4255. PubMed ID: 29769207
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization.
    Becker W; Olkhanud PB; Seishima N; Moreno PA; Goldfarbmuren KC; Maeng HM; Berzofsky JA
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38955422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
    Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
    J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
    Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for HPV negative head and neck squamous cell carcinoma.
    Jiang B; Elkashif A; Coulter JA; Dunne NJ; McCarthy HO
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189138. PubMed ID: 38889878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.
    von Witzleben A; Wang C; Laban S; Savelyeva N; Ottensmeier CH
    Cells; 2020 Sep; 9(9):. PubMed ID: 32942747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
    Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
    Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
    Saito S; Kono M; Nguyen HCB; Egloff AM; Messier C; Lizotte P; Paweletz C; Adkins D; Uppaluri R
    Clin Cancer Res; 2024 May; 30(9):1934-1944. PubMed ID: 38372707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.
    Weed DT; Zilio S; Reis IM; Sargi Z; Abouyared M; Gomez-Fernandez CR; Civantos FJ; Rodriguez CP; Serafini P
    Front Immunol; 2019; 10():1206. PubMed ID: 31214178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.